Point72 Asset Management’s AnaptysBio ANAB Stock Holding History

Point72 Asset Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-20,000	Closed	-$2M	–	947
2018 Q3	$2M	Buy	+20,000	New	+$1.66M	0.01%	761

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Point72 Asset Management's ANAB Position: Q2 2026 in Review

Point72 Asset Management sold out of AnaptysBio (ANAB) in Q2 2026, closing a stake of 55,303 shares — an estimated $3.07M sold.

Point72 Asset Management first reported a position in ANAB in Q1 2019 and held it in 21 quarters. The position peaked at $93.7M in Q4 2025. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

Point72 Asset Management reported no remaining AnaptysBio position as of Q2 2026 after selling out during the quarter.
Point72 Asset Management sold 55,303 AnaptysBio shares in Q2 2026, an estimated $3.07M.
Point72 Asset Management first reported a position in AnaptysBio in Q1 2019 and held it in 21 quarters.
Point72 Asset Management's AnaptysBio position peaked at $93.7M in Q4 2025.
213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.